Sweden: Hansa Biopharma submits draft registration with SEC for potential US IPO

Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has confidentially submitted a draft registration statement to the U.S. Securities and Exchange Commission (SEC) relating to a potential IPO of American Depositary Shares (ADS) in the US. The ADS will represent Hansa’s ordinary shares. Listing of the ADS will be on Nasdaq. The number…

You must be a HMI Subscriber to view this content.

Subscribe Now »